TiumBio Co., Ltd.
Biopharmaceutical firm developing therapeutics for rare and incurable diseases.
321550 | KO
Overview
Corporate Details
- ISIN(s):
- KR7321550006
- LEI:
- Country:
- South Korea
- Address:
- 경기도 성남시 수정구 창업로40번길 30 6층 (시흥동, 판교아이티센터), 성남시
- Website:
- http://www.tiumbio.com/en/
Description
TiumBio is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapeutics for rare and incurable diseases. The company's pipeline targets conditions with high unmet medical needs, including fibrotic diseases, cancer, and rare hematological disorders. Its lead assets include Merigolix (TU2670), an oral GnRH antagonist in clinical development for endometriosis and uterine fibroids, and TU7710, a long-acting recombinant activated factor VII for hemophilia. TiumBio also develops small molecule antagonists targeting the TGF-β signaling pathway for applications in oncology and fibrosis. The company advances its programs through clinical development and strategic global partnerships.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-12-16 00:00 |
주주명부폐쇄기간또는기준일설정
|
Korean | 4.2 KB | ||
| 2025-08-14 00:00 |
반기보고서 (2025.06)
|
Korean | 1.8 MB | ||
| 2025-07-22 00:00 |
전환사채(해외전환사채포함)발행후만기전사채취득
|
Korean | 9.6 KB | ||
| 2025-07-07 00:00 |
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 28.8 KB | ||
| 2025-05-27 00:00 |
투자판단관련주요경영사항(임상시험계획승인신청등결정) (혈우병 치료신약 TU7710의 아르메니아 임상 1b상 시험계획(IN…
|
Korean | 12.2 KB | ||
| 2025-05-15 00:00 |
분기보고서 (2025.03)
|
Korean | 2.0 MB | ||
| 2025-04-28 00:00 |
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 27.1 KB | ||
| 2025-04-28 00:00 |
주식등의대량보유상황보고서(일반)
|
Korean | 149.4 KB | ||
| 2025-04-28 00:00 |
주식등의대량보유상황보고서(일반)
|
Korean | 168.5 KB | ||
| 2025-04-23 00:00 |
기업설명회(IR)개최
|
Korean | 6.9 KB | ||
| 2025-03-27 00:00 |
정기주주총회결과
|
Korean | 24.3 KB | ||
| 2025-03-27 00:00 |
증권발행결과(자율공시)
|
Korean | 6.2 KB | ||
| 2025-03-24 00:00 |
[기재정정]주요사항보고서(교환사채권발행결정)
|
Korean | 36.5 KB | ||
| 2025-03-24 00:00 |
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 25.5 KB | ||
| 2025-03-20 00:00 |
투자판단관련주요경영사항 (호흡기질환 치료제 개발 프로그램 NCE401 기술이전 계약해지 및 권리 반환)
|
Korean | 6.2 KB |
Automate Your Workflow. Get a real-time feed of all TiumBio Co., Ltd. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for TiumBio Co., Ltd.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for TiumBio Co., Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
